Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 11 | 2024 | 136 | 1.480 |
Why?
|
| Eflornithine | 5 | 2023 | 18 | 0.680 |
Why?
|
| Behavioral Sciences | 1 | 2020 | 2 | 0.670 |
Why?
|
| Leadership | 1 | 2020 | 86 | 0.630 |
Why?
|
| Clergy | 1 | 2019 | 13 | 0.600 |
Why?
|
| Terminal Care | 1 | 2019 | 54 | 0.580 |
Why?
|
| Health Personnel | 1 | 2019 | 277 | 0.490 |
Why?
|
| Sodium-Potassium-Chloride Symporters | 2 | 2004 | 5 | 0.410 |
Why?
|
| Bronchi | 2 | 2004 | 45 | 0.400 |
Why?
|
| Antineoplastic Agents | 4 | 2022 | 1019 | 0.370 |
Why?
|
| Survivors | 1 | 2013 | 152 | 0.370 |
Why?
|
| Tretinoin | 3 | 2008 | 50 | 0.330 |
Why?
|
| Oncogene Proteins | 2 | 2012 | 21 | 0.300 |
Why?
|
| Health Behavior | 1 | 2013 | 575 | 0.300 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2024 | 154 | 0.300 |
Why?
|
| Sp3 Transcription Factor | 2 | 2008 | 8 | 0.290 |
Why?
|
| Immunoglobulins | 1 | 2008 | 39 | 0.280 |
Why?
|
| Child | 8 | 2024 | 3443 | 0.270 |
Why?
|
| Neoplasms | 2 | 2021 | 1377 | 0.270 |
Why?
|
| Genes, myc | 2 | 2003 | 31 | 0.260 |
Why?
|
| Nuclear Proteins | 2 | 2012 | 333 | 0.260 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2004 | 91 | 0.240 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 220 | 0.240 |
Why?
|
| Blood Preservation | 1 | 2004 | 6 | 0.210 |
Why?
|
| Blood Banks | 1 | 2004 | 10 | 0.210 |
Why?
|
| Blood Specimen Collection | 1 | 2004 | 12 | 0.210 |
Why?
|
| Nervous System Neoplasms | 1 | 2003 | 2 | 0.210 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2003 | 2 | 0.210 |
Why?
|
| Fetal Blood | 1 | 2004 | 48 | 0.200 |
Why?
|
| Humans | 20 | 2024 | 43102 | 0.200 |
Why?
|
| Medulloblastoma | 1 | 2023 | 4 | 0.200 |
Why?
|
| Cerebellar Neoplasms | 1 | 2023 | 4 | 0.200 |
Why?
|
| Trachea | 1 | 2002 | 25 | 0.190 |
Why?
|
| Muscle, Smooth | 1 | 2002 | 58 | 0.190 |
Why?
|
| Fibroblasts | 1 | 2004 | 281 | 0.190 |
Why?
|
| Immune Evasion | 1 | 2021 | 17 | 0.180 |
Why?
|
| Vault Ribonucleoprotein Particles | 1 | 2020 | 1 | 0.170 |
Why?
|
| Chromosome Disorders | 1 | 2020 | 8 | 0.170 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2020 | 8 | 0.170 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2020 | 31 | 0.170 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 38 | 0.160 |
Why?
|
| Autistic Disorder | 1 | 2020 | 39 | 0.160 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2020 | 108 | 0.160 |
Why?
|
| Patient Care Team | 1 | 2020 | 60 | 0.160 |
Why?
|
| Health Resources | 1 | 2019 | 37 | 0.150 |
Why?
|
| Child, Preschool | 5 | 2021 | 1546 | 0.140 |
Why?
|
| Pediatrics | 1 | 2019 | 70 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 307 | 0.140 |
Why?
|
| Faculty | 1 | 2019 | 105 | 0.140 |
Why?
|
| Disease-Free Survival | 3 | 2023 | 116 | 0.130 |
Why?
|
| Mutation | 1 | 2021 | 1177 | 0.120 |
Why?
|
| Curriculum | 1 | 2019 | 318 | 0.120 |
Why?
|
| Polyamines | 1 | 2015 | 32 | 0.110 |
Why?
|
| Down-Regulation | 2 | 2008 | 456 | 0.100 |
Why?
|
| Blotting, Western | 2 | 2008 | 883 | 0.100 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2013 | 82 | 0.100 |
Why?
|
| Hawaii | 2 | 2013 | 2011 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2020 | 54 | 0.090 |
Why?
|
| Phenotype | 1 | 2015 | 780 | 0.090 |
Why?
|
| Prognosis | 3 | 2021 | 861 | 0.090 |
Why?
|
| Motor Activity | 1 | 2013 | 437 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2012 | 200 | 0.080 |
Why?
|
| Cell Survival | 2 | 2004 | 945 | 0.080 |
Why?
|
| Phosphoproteins | 1 | 2012 | 206 | 0.080 |
Why?
|
| Adolescent | 3 | 2021 | 6081 | 0.080 |
Why?
|
| Recurrence | 2 | 2023 | 152 | 0.080 |
Why?
|
| Survival Rate | 2 | 2021 | 355 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 968 | 0.070 |
Why?
|
| Etoposide | 2 | 2020 | 21 | 0.070 |
Why?
|
| Female | 6 | 2021 | 24698 | 0.070 |
Why?
|
| Alcohol Drinking | 1 | 2013 | 609 | 0.070 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2008 | 54 | 0.070 |
Why?
|
| Cell Movement | 1 | 2012 | 655 | 0.070 |
Why?
|
| Immunoprecipitation | 1 | 2008 | 127 | 0.070 |
Why?
|
| Young Adult | 2 | 2021 | 5080 | 0.070 |
Why?
|
| Diet | 1 | 2013 | 826 | 0.070 |
Why?
|
| Protein Transport | 1 | 2008 | 296 | 0.060 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2008 | 185 | 0.060 |
Why?
|
| Male | 5 | 2021 | 23409 | 0.060 |
Why?
|
| Smoking | 1 | 2013 | 1024 | 0.060 |
Why?
|
| Infant | 2 | 2021 | 1175 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2012 | 2676 | 0.050 |
Why?
|
| Bumetanide | 1 | 2004 | 3 | 0.050 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2004 | 5 | 0.050 |
Why?
|
| Furosemide | 1 | 2004 | 12 | 0.050 |
Why?
|
| G1 Phase | 1 | 2004 | 31 | 0.050 |
Why?
|
| Diuretics | 1 | 2004 | 51 | 0.050 |
Why?
|
| Blood Cells | 1 | 2004 | 8 | 0.050 |
Why?
|
| S Phase | 1 | 2004 | 36 | 0.050 |
Why?
|
| Washington | 1 | 2004 | 38 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2004 | 53 | 0.050 |
Why?
|
| Blood Donors | 1 | 2004 | 20 | 0.050 |
Why?
|
| Cell Count | 1 | 2004 | 145 | 0.050 |
Why?
|
| Biological Transport | 1 | 2004 | 204 | 0.050 |
Why?
|
| Propensity Score | 1 | 2023 | 59 | 0.050 |
Why?
|
| Nifurtimox | 1 | 2023 | 1 | 0.050 |
Why?
|
| Topotecan | 1 | 2023 | 5 | 0.050 |
Why?
|
| Cell Division | 1 | 2004 | 311 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2020 | 1604 | 0.050 |
Why?
|
| Sp1 Transcription Factor | 1 | 2003 | 46 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 59 | 0.050 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2002 | 39 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 173 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2004 | 259 | 0.050 |
Why?
|
| Fetus | 1 | 2002 | 101 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2002 | 240 | 0.050 |
Why?
|
| Registries | 1 | 2004 | 437 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2022 | 51 | 0.040 |
Why?
|
| Daunorubicin | 1 | 2020 | 3 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2020 | 8 | 0.040 |
Why?
|
| Cytarabine | 1 | 2020 | 10 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2022 | 144 | 0.040 |
Why?
|
| Chromosome Deletion | 1 | 2020 | 53 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2002 | 934 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2004 | 1621 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 561 | 0.040 |
Why?
|
| RNA | 1 | 2022 | 266 | 0.040 |
Why?
|
| Genomics | 1 | 2022 | 293 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 760 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 1067 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2003 | 735 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1063 | 0.030 |
Why?
|
| Apoptosis | 1 | 2004 | 1568 | 0.030 |
Why?
|
| Ornithine Decarboxylase | 1 | 2015 | 10 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2022 | 2544 | 0.030 |
Why?
|
| Safety | 1 | 2015 | 54 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2012 | 23 | 0.020 |
Why?
|
| COS Cells | 1 | 2012 | 68 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2012 | 23 | 0.020 |
Why?
|
| Integrins | 1 | 2012 | 54 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2012 | 61 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 98 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2012 | 238 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2012 | 161 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 1082 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2012 | 1271 | 0.020 |
Why?
|
| Adult | 1 | 2021 | 13872 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2004 | 7 | 0.010 |
Why?
|
| Public Policy | 1 | 2004 | 36 | 0.010 |
Why?
|
| Genetics, Population | 1 | 2004 | 121 | 0.010 |
Why?
|
| Neurofibromin 1 | 1 | 2003 | 3 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2003 | 49 | 0.010 |
Why?
|
| Drosophila | 1 | 2003 | 152 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 508 | 0.010 |
Why?
|
| Base Sequence | 1 | 2003 | 983 | 0.010 |
Why?
|
| Animals | 2 | 2012 | 16992 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 526 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 1542 | 0.010 |
Why?
|
| United States | 1 | 2004 | 5205 | 0.010 |
Why?
|